Tech Company Financing Transactions
Jasper Therapeutics Funding Round
On 12/10/2019, Jasper Therapeutics raised $35 million in Series A funding from Abingworth, Qiming Ventures and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
12/10/2019
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series A
Investors
Proceeds Purpose
The proceeds will be used to advance the clinical development of the company's lead product candidate, JSP191, which is designed to replace or reduce the toxicity of chemotherapy and radiation therapy as a conditioning regimen to prepare patients for hematopoietic cell transplant.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3000 Sand Hill Rd. B1-145
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Website
Email Address
Overview
Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper's lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
William Lis
Chief Financial Officer
Jeet Mahal
Co-Founder
Judith Shizuru
VP - Operations
Susan Prohaska
VP - R & D
Wendy Pang
Browse more venture capital transactions:
Prev: 12/10/2019: WalkMe venture capital transaction
Next: 12/10/2019: Code Dx venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs